S
17.89
2.04 (12.87%)
| Previous Close | 15.85 |
| Open | 16.13 |
| Volume | 4,556,625 |
| Avg. Volume (3M) | 3,442,495 |
| Market Cap | 13,885,548,544 |
| Price / Book | 22.53 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.340 |
| Total Debt/Equity (MRQ) | 1.87% |
| Current Ratio (MRQ) | 10.63 |
| Operating Cash Flow (TTM) | -173.14 M |
| Levered Free Cash Flow (TTM) | -104.80 M |
| Return on Assets (TTM) | -52.50% |
| Return on Equity (TTM) | -123.93% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Summit Therapeutics Inc. | Bearish | Mixed |
AIStockmoo Score
0.3
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.25 |
|
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 84.32% |
| % Held by Institutions | 13.52% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Polymer Capital Management (Hk) Ltd | 31 Dec 2025 | 1,421,155 |
| Apeiron Capital Ltd | 31 Mar 2026 | 1,309,141 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |